Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC Jr, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME. Trendowski MR, et al. Among authors: kollmannsberger c. Clin Cancer Res. 2019 Oct 1;25(19):5913-5924. doi: 10.1158/1078-0432.CCR-19-0113. Epub 2019 Jul 11. Clin Cancer Res. 2019. PMID: 31296530 Free PMC article.
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C. Bokemeyer C, et al. Among authors: kollmannsberger c. J Clin Oncol. 1999 Nov;17(11):3450-6. doi: 10.1200/JCO.1999.17.11.3450. J Clin Oncol. 1999. PMID: 10550141
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. Among authors: kollmannsberger ck. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J. Lorch A, et al. Among authors: kollmannsberger c. J Clin Oncol. 2011 Jun 1;29(16):2178-84. doi: 10.1200/JCO.2010.32.6678. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444870
Sequelae of treatment in long-term survivors of testis cancer.
Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN. Abouassaly R, et al. Among authors: kollmannsberger c. Eur Urol. 2011 Sep;60(3):516-26. doi: 10.1016/j.eururo.2011.05.055. Epub 2011 Jun 12. Eur Urol. 2011. PMID: 21684072 Review.
Contemporary management of postchemotherapy testis cancer.
Daneshmand S, Albers P, Fosså SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L. Daneshmand S, et al. Among authors: kollmannsberger c. Eur Urol. 2012 Nov;62(5):867-76. doi: 10.1016/j.eururo.2012.08.014. Epub 2012 Aug 20. Eur Urol. 2012. PMID: 22938868 Review.
The conundrum of clinical trials in adult germ-cell tumours.
Powles T, Kollmannsberger C, Feldman DR. Powles T, et al. Among authors: kollmannsberger c. Lancet Oncol. 2013 Jan;14(1):14-5. doi: 10.1016/S1470-2045(12)70561-2. Lancet Oncol. 2013. PMID: 23276363 No abstract available.
295 results